je.st
news
Tag: england
England, Europe at Risk of Major Sea Level Rise
2015-06-18 23:04:00| Climate Ark Climate Change & Global Warming Newsfeed
Nature World News: According to the results published in the journal Climate Research, the seas around Scandinavia, England, the Netherlands and northern Germany will rise by up to about 1.5 meters (~5 feet) in this century. "Even though the oceans are rising, they do not rise evenly across the globe. This is partly due to regional changes in the gravitational field and land uplift," researcher Aslak Grinsted, with the Niels Bohr Institute at the University of Copenhagen, said in a statement. Gravity over the...
Results from Investigational IMPROVE-IT Study of VYTORIN (ezetimibe and simvastatin) Published in the New England Journal of Medicine
2015-06-03 23:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment with VYTORIN (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Tracy Ogden, (267) 305-2301orInvestor:Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
results
study
journal
First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Mercks KEYTRUDA (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine
2015-05-29 20:05:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Early Findings Show DNA Mismatch Repair-Deficient Colorectal and Other Tumors Highly Responsive to Checkpoint Blockade with Anti-PD-1 Therapy Merck Plans to Initiate Phase 2 Registrational Study with KEYTRUDA (KEYNOTE-164) to Evaluate MMR-Deficiency in Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the first study evaluating the correlation of benefit with an immunotherapy based on DNA mismatch repair (MMR) deficiency, a well-established form of genetic instability in many cancers characterized by the loss of function of the MMR pathway. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
just the Winners - International Wine Challenge 2015: Austria, Brazil, Canada, Chile, England
2015-05-20 19:05:00| Daily beverage news and comment - from just-drinks.com
Earlier this month, the International Wine Challenge released the list of winners for 2015. In this second part, we have the gold medalists from Austria, Brazil, Canada, Chile and England.
Tags: international
canada
england
brazil
Bank of England cuts UK growth rate
2015-05-13 12:43:36| BBC News | Business | UK Edition
The Bank of England cuts its 2015 growth forecast from 2.9% to 2.5%, as governor Mark Carney unveils his quarterly inflation report.
Tags: rate
bank
growth
england
Sites : [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] next »